AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday
AstraZeneca agreed to license obesity drug candidates from CSPC Pharmaceutical in a deal worth up to $18.5 billion, paying $1.2 billion upfront. AstraZeneca shares rose 0.65% in London, while CSPC shares fell nearly 12% in Hong Kong. The deal gives AstraZeneca rights outside Greater China and includes a once-monthly GLP-1/GIP agonist entering Phase I trials. AstraZeneca will also delist its ADS from Nasdaq and move to the NYSE.
